The WM Trial has ended and is no longer enrolling

Study results will be shared on this site when available

About the WM Trial

The WM Trial clinical research study is no longer enrolling. Results of this phase 1b study will help determine at what dosage the investigational study drug, mavorixafor, is well-tolerated by people with WM in combination with ibrutinib.

Sign Up for Updates

Enter your email address to receive updates about the WM Trial and other X4 Pharmaceuticals news.

    I hereby authorize X4 Pharmaceuticals, together with any individuals or entities working for or on behalf of X4 Pharmaceuticals, to contact me by mail or email for marketing purposes, including to conduct market research or to obtain similar information from me, and to provide information to me about X4’s drug candidates, services, programs or other potential topics of interest. I understand that I may withdraw the above authorization and choose not to receive future information or updates from X4 Pharmaceuticals at any time by contacting X4 Pharmaceuticals at the following address: